A collaborative research team consisting of Professor Keisuke Nimura of the Division of Gene Therapy Science, GIAR at Gunma University, together with Lecturer Koji Hatano and graduate student Masaru Tani from the Department of Urology, The University of Osaka Graduate School of Medicine, has advanced research on combination therapies that leverage the mechanism of synthetic lethality, with the aim of developing new treatment strategies for prostate cancer.

In this study, the team searched for molecules that enhance the efficacy of PARP inhibitors and discovered that suppressing LIG1 strengthens therapeutic effects. The combination with an LIG1 inhibitor was shown to have the potential to inhibit tumor growth, offering promise as a new treatment option for prostate cancer.

■Title
Development of a Synthetic Lethality-Based Combination Therapy Using LIG1 and PARP Inhibitors for Prostate Cancer

Masaru Tani¹, Koji Hatano^1,＊, Yu Ishizuya¹, Toshiki Oka¹, Tomohiro Kanaki¹, Shunsuke Inoguchi¹, Akihiro Yoshimura¹, Yuki Horibe¹, Yutong Liu¹, Sassi Nesrine¹, Yohei Okuda¹, Akinaru Yamamoto¹, Toshihiro Uemura¹, Gaku Yamamichi¹, Takuji Hayashi¹, Yoshiyuki Yamamoto¹, Taigo Kato¹, Atsunari Kawashima¹, Takao Yamaguchi², Satoshi Obika², Kosuke Yusa³, Norio Nonomura¹, Keisuke Nimura^4,＊
＊corresponding authors
1　Department of Urology, The University of Osaka Graduate School of Medicine, Suita, Japan
2　Graduate School of Pharmaceutical Sciences, The Universityof Osaka, Suita, Japan
3　Stem Cell Genetics, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan
4　Division of Gene Therapy Science,Gunma University Initiative for Advanced Research, Gunma University, Maebashi, Japan

■Journal
Cancer Science　(IF: 4.3)
DOI　10.1111/cas.70194

■Link
Dr.NIMURA Laboratory